The renin-angiotensin system (RAS) is involved in inflammation. The signaling via the ANG II type 1 receptor in human lymphocytes and monocytes, which play key roles in pathophysiology of glomerulonephritis (GN), can enhance inflammation. However, the role of the (pro)renin receptor [(P)RR], a component of the RAS, in inflammatory reactions is unknown. We assessed whether (P)RR is expressed in human lymphocytes and monocytes by RT-PCR, Western blotting, flow cytometry, and immunohistochemistry, and whether (P)RR functions in inflammation. (P)RR mRNA and protein were expressed in human peripheral blood mononuclear cells (PBMCs). Flow cytometric analysis revealed high expression of (P)RR on monocytes. (P)RR was present on PBMCs, infiltrating lymphocytes, and macrophages around glomeruli with a crescent in anti-neutrophil cytoplasmic antibody (ANCA)-associated GN. Renin stimulation of PBMCs from healthy subjects in the presence of the ANG II type 1 receptor and ANG II type 2 receptor blockers induced ERK1/2 phosphorylation and release of IL-6 and expression of cyclooxygenase-2 (COX-2). The increases in cytokine release and COX-2 expression were inhibited in the presence of an ERK1/2 inhibitor. (P)RR knockdown by small interfering RNA in U937 cells, a human leukemic monocyte lymphoma cell line, significantly decreased ERK1/2 phosphorylation after renin stimulation. Thus (P)RR expressed in human inflammatory cells might contribute to inflammation in ANCA-associated GN.
INFLAMMATORY CELLS SUCH AS lymphocytes and macrophages infiltrate around the glomeruli and tubulointerstitial in glomerulonephritis (GN) and play a role in the progression of renal injury. Classically, B lymphocytes producing immunoglobulins (Ig) are involved in the pathogenesis of GN. T lymphocytes can abrogate inflammatory activity, leading to the amelioration of GN. In addition, macrophages have key functions in inflammation, tissue repair, and remodeling (30, 33) . However, activation of these cells in the pathogenesis of GN is poorly understood.
The renin-angiotensin system (RAS) is essential for blood pressure control by regulating salt metabolism and body fluid volume. Angiotensin (ANG) II contributes to the pathophysiology of renal disease, cardiac hypertrophy (32) , and atherosclerosis (47) by signaling through the ANG II type 1 receptor (AT 1 R). AT 1 R expressed by human B and T lymphocytes and monocytes (39) can enhance immune reactions (9) . ANG II has significant proinflammatory actions in the vascular wall, including the production of reactive oxygen species, inflammatory cytokines, and adhesion molecules (7) . Furthermore, the inhibition of the RAS is an effective treatment for autoimmune nephritis (17, 18) . The therapeutic use of an angiotensinconverting enzyme (ACE) inhibitor reduced proteinuria and glomerular injury in a mouse model of lupus nephritis (18) . However, the mechanism by which the RAS stimulates inflammatory cells is not fully understood.
The (pro)renin receptor [(P)RR], a specific receptor for renin and prorenin, is an important member of the RAS (36) . When prorenin binds to (P)RR, it becomes the active form and produces ANG I from angiotensinogen. Although full-length and soluble forms of (P)RR have been isolated (10) , the specific role of each is not known. In addition, (P)RR activation triggers MAPK ERK1/2 phosphorylation, which stimulates the production of transforming growth factor-␤1 (TGF-␤1) that mediates cell proliferation and fibrosis (35, 50) . Thus (P)RR could act as an intracellular signaling receptor independently of ANG II and participate in the inflammatory reaction, including GN. However, there is no direct evidence that (P)RR is responsible for the activation of inflammatory cells involved in GN. Therefore, we hypothesized that (P)RR expressed in human lymphocytes and monocytes may participate in the activation of inflammatory cells and the progression of GN. To clarify this, we examined (P)RR expression in primary isolated human lymphocytes and monocytes and investigated ERK1/2 phosphorylation by renin stimulation using primary human lym-phocytes and monocytes and a human leukemic monocyte lymphoma cell line (U937). (P)RR is expressed by human lymphocytes and monocytes and is responsible for inflammation by activation of ERK1/2 via the renin-(P)RR pathway and inflammatory cytokine release. In addition, (P)RR was expressed by inflammatory cells present during active anti-neutrophil cytoplasmic antibody (ANCA)-associated GN.
MATERIALS AND METHODS
Human tissues and blood sampling. The study protocol was approved by the Institutional Review Board of the Tohoku University School of Medicine. All participants gave written informed consent after a full explanation of the purpose and potential risk involved in participating in the study.
Renal sections were obtained by renal biopsy of three patients diagnosed with ANCA-associated GN and three patients diagnosed with minimal-change nephrotic syndrome (MCNS). Venous blood was obtained from 12 healthy volunteers (6 men and 6 women, age range 21-45 yr). Plasma was collected concurrently to analyze biochemical parameters. Human brain tissues, pituitary glands, hearts, kidneys, and adrenal glands were obtained at autopsy for RT-PCR analysis and stored at Ϫ80°C until RNA extraction (43, 44) . The tissues had no macroscopic pathological abnormalities.
Lymphocyte isolation. Peripheral blood mononuclear cells (PBMCs) were obtained as previously described (6) . Briefly, PBMCs were prepared by layering whole blood on Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) and centrifuged at 300 g at room temperature for 20 min. The interphase of mononuclear leukocytes was carefully aspirated, washed two times in PBS (Sigma-Aldrich, Munich, Germany), and centrifuged at 1,500 rpm for 5 min. Cells were then resuspended in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with penicillin G (100 IU/ml, Sigma-Aldrich) and streptomycin (100 g/ml, Sigma-Aldrich). T cells, natural killer (NK) cells, and monocytes were separated from PBMCs by magnetically activated cell sorting (MACS).
Immunohistochemistry of (P)RR in human crescentic GN and PBMCs. Renal biopsies were fixed in 95% ethanol and paraffin embedded. Tissue blocks were cut into 1.5-m sections for immunostaining and periodic acid-Schiff (PAS) staining. For immunostaining, paraffin sections were deparaffinized and incubated in methanol containing 0.3% H 2O2 for 30 min and digested with collagenase to examine the effect of proteolytic or glycolytic enzymes on the reactivity of surface antigens. Cytospin slides were prepared from PBMCs after incubation with fixation buffer (00-8222-49, eBioscience, San Diego, CA) for 30 min. Both tissue and PBMCs slides were incubated in primary antibody overnight at 4°C in protein block serum-free solution (X0909, Dako, Glostrup, Denmark). Primary antibodies against lymphocytes were used as previously described (37) . Antiserum against (P)RR was raised in a rabbit by injection of a human (P)RR fragment corresponding to 224 -237 amino acids conjugated to BSA (19, 20) . After washing, slides were incubated with Alexa Fluor 555 goat anti-rabbit antibody (A-21428, Life Technologies, Grand Island, NY) and Alexa Fluor 488 goat anti-mouse antibody (A-11001, Life Technologies) for 30 min in protein block serum-free solution. Then, slides were embedded in DAPI-Fluoromount-G (SouthernBiotech, Birmingham, AL) and observed by TCS-SP8 confocal microscopy (Leica, Wetzlar, Germany).
mRNA expression. Total RNA was extracted by Isogen (Nippon Gene, Toyama, Japan). Total RNA (4 g) was reverse transcribed with 400 U of reverse transcriptase (PrimeScript; TaKaRa, Otsu, Japan) using an oligo (dT) primer, as previously described (19, 42) .
PCR was performed in a total volume of 20 l containing 80 ng of cDNA, 0.2 mmol/l of each deoxynucleotide triphosphate, 0.25 mol/l of each primer, and 0.4 units of Taq DNA polymerase (Promega, Madison, WI). Primer sequences for (P)RR (GenBank accession no. NM005765) were as follows: sense (exon 8) 5=-CCTCCCTCATTAGGAAGA-CAAGGAC-3=, and anti-sense (exon 9) 5=-TCGAATCTTCTGGTTT-GTCATCCT-3=. Expression of GAPDH mRNA was used as an internal control (40 -42) . After heating at 94°C for 2 min, denaturation, annealing and elongation were carried out at 94°C for 15 s, 64°C for 30 s, and 72°C for 1 min, respectively, and the reactions were repeated for 25 cycles, followed by incubation at 72°C for 5 min.
(P)RR expression in lymphocytes and monocytes and cyclooxygenase-2 (COX-2) in PBMCs were quantified by real-time PCR. Five nanograms of cDNA was amplified in duplicate using SYBER Premix Ex Taq II (TaKaRa Bio) on CFX96 (Bio-Rad). The same primers of (P)RR as above were used. Primers of COX-2 (HA143872) and GAPDH (HA067812) were purchased from TaKaRa Bio. After heating at 95°C for 2 min, denaturation, annealing and elongation were carried out at 95°C for 5 s and 60°C for 20 s, respectively, and the reactions were repeated for 39 cycles, followed by incubation at 65°C for 5 s.
Western blot analysis. PBMCs were collected by centrifuging at 1,500 rpm for 10 min and resuspended with RIPA buffer (Cell Signaling Technology, Danvers, MA) containing a protease inhibitor (Roche, Basel, Switzerland), Laemmli Sample Buffer (161-0737, Bio-Rad, Hercules, CA), and ␤-mercaptoethanol (Bio-Rad). U937 cells were lysed with RIPA buffer (Cell Signaling Technology) containing a protease inhibitor (Roche) and phosphatase inhibitor (Sigma-Aldrich) after renin stimulation. After boiling at 95°C for 5 min, protein extracts were separated by 12% SDS-PAGE for 90 min at 150 V and transferred electrophoretically to polyvinylidene difluoride membranes (Bio-Rad) for 1 h at 100 V, 4°C. Membranes were incubated in TBS (10 mmol/l Tris·HCl, 150 mmol/l NaCl) with 5% nonfat dry milk or 10% BSA for 1 h, then incubated with primary antibody [anti-(P)RR, 1:5,000; anti-ERK, 1:1,000, 4695S, Cell Signaling; anti-p-ERK, 1:1,000, 4377S, Cell Signaling Technology] overnight at 4°C in TBS with 2% nonfat dry milk or 5% BSA. Membranes were washed three times in TBS with 0.08% Tween 20 for a total of 30 min and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (anti-rabbit IgG, 1:5,000, sc-2,004; anti-mouse IgG, 1:5,000, sc-2005; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h in TBS with 2% nonfat dry milk or 5% BSA. After washing three times in TBS with 0.08% Tween 20, chemiluminescence (ECL Western blotting detection system; Amersham, Arlington Heights, IL) was measured using VersaDocMP5000 (BioRad). Expression of ␤-actin (1:5,000, sc-47778, Santa Cruz Biotechnology) was used as an internal control. Specificity of the antiserum against (P)RR was examined using an absorption test, performed using antiserum incubated with an excess amount of human (P)RR 224 -237 (10 nmol) for 20 h at 4°C prior use.
Flow cytometric analysis. Six-color flow cytometric analyses were performed on a FACS Canto II, with a FACS Aria II (Becton Dickinson, Franklin Lakes, NJ) for cell sorting. Within 30 min after cell isolation, PBMCs (3 ϫ 10 5 cells) were stained for 30 min on ice using the corresponding antibodies and washed three times with PBS after blocking with goat IgG to avoid reactivity to the secondary antibody. Three samples used different antibody combinations for staining as follows: 1) anti-(P)RR antibody-PE, anti-CCR7-FITC, anti-CD4-PerCP, anti-CD45RA-APC, anti-CD3-V450, anti-CD8-APC-Cy7 or anti-(P)RR antibody-PE, anti-CD19-PerCP, and anti-CD56-Pacific blue; 2) nonimmune rabbit serum and anti-CD antibodies as above; and 3) nonimmune rabbit serum and isotype control. Monocytes were analyzed by gating on the monocyte population assessed by forward-and side-scatter dot plots. Data were analyzed by FlowJo software (Tree Star, Ashland, OR). After immunostaining, cells were resuspended in PBS and analyzed immediately by flow cytometry with DIVA software (Becton Dickinson). The cutoff value of fluorescence was 99% negative for the control.
To analyze (P)RR expression on lymphocytes and monocytes, isolated PBMCs were incubated with an anti-(P)RR antibody, followed by a PE-conjugated secondary goat-anti-rabbit antibody (1:100, 20303, Imgenex, San Diego, CA) for 30 min on ice at each step. Serum obtained from the rabbit before immunization with the peptide fragment (nonimmune rabbit serum) was used as a respective isotype control for the anti-(P)RR antibody.
After renin stimulation, cells were fixed in fixation buffer (00-8222-49, eBioscience) for 20 min at room temperature and washed two times with permeabilization buffer (00-8333-56, eBioscience). Then, cells were stained for 1 h at room temperature using phospho-ERK (p-ERK) antibody, followed by PE-conjugated secondary goatanti-rabbit antibody (1:100, 20303, Imgenex) for 30 min at room temperature.
ERK1/2 phosphorylation by renin stimulation. To prevent signaling through AT 1R and the ANG II type 2 receptor (AT2R), isolated PBMCs were preincubated in RPMI 1640 containing penicillin G (100 IU/ml), streptomycin (100 g/ml), AT1R blocker losartan (10 mol/l), and AT2R blocker PD123319 (10 mol/l) for 60 min. To examine whether renin stimulation induces cytokine releasing through the ERK1/2 pathway, a specific ERK1/2 inhibitor, U0126 (10 mol/l, U120, Sigma-Aldrich), was incubated with RPMI 1640, penicillin G (100 IU/ml), streptomycin (100 g/ml), AT 1R blocker losartan (10 mol/l), and AT2R blocker PD123319 (10 mol/l) for 60 min. Thereafter, cells were incubated in medium containing human recombinant renin (2 or 20 nmol/l, R2779, Sigma-Aldrich) for 0, 6, and 24 h. We used 50 mmol/l Tris·HCl buffer as a vehicle control.
Measurement of renin-induced cytokine release by cytometric bead array. Release of cytokines (IL-2, IL-4, IL-6, IL-10, IFN-␥, and TNF-␣) released from lymphocytes and monocytes were measured by a BD Human Th1/Th2 Cytokine cytometric bead array kit II (BectonDickinson) according to the manufacturer's instructions. Fifty microliters of supernatant was stained with a suspension containing a mixture of human cytokine capture beads and a PE detection reagent. After 3 h of incubation, samples were washed and analyzed. Standards provided with the kit were appropriately diluted and used in parallel for preparation of the standard curves.
Cell culture and small interfering RNA transfection. U937 cells (American Type Culture Collection CRL-1593.2) were cultured in RPMI 1640 supplemented with 10% FBS (Life Technologies), penicillin G (100 IU/ml), streptomycin (100 g/ml), and pyruvate acid (100 mmol/l) at 37°C in humidified air with 5% CO 2. Medium was changed every 3 days. Cells were serum starved for 24 h before the renin stimulation experiments were performed. (P)RR small interfering RNA (siRNA; LQ-013647-01-0005, Thermo Scientific) or nontargeting control siRNA (D-001810-10-05, Thermo Scientific) were transfected into U937 cells by electroporation (4D-Nucleofector, . A: expression of (P)RR mRNA in human peripheral blood mononuclear cells (PBMCs), kidney, adrenal gland, heart, frontal lobe, and pituitary gland. Reverse transcription (Ϫ; samples without RTase treatment) indicates negative controls (n ϭ 2). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. B: (P)RR mRNA in subpopulations of lymphocytes and monocytes by real-time PCR (n ϭ 12). Values are presented as the median (central line), interquartile range (box), and range (whiskers). *P Ͻ 0.05. C: expression of (P)RR protein in human PBMCs (n ϭ 2) by Western blot analysis. Both full-length (39 kDa) and soluble form (28 kDa) of (P)RR were expressed in PBMCs. D: expression of (P)RR protein in human PBMCs (n ϭ 3) by Western blot analysis. (P)RR antiserum (ϩ), PBMC samples treated with antiserum against (P)RR; Absorption, PBMC samples treated with antiserum against (P)RR preabsorbed with synthetic human (P)RR224-237. (P)RR gave a strong signal with a molecular weight of 39 kDa. As an internal control, the membranes were rehybridized with ␤-actin antibody. Lonza, Switzerland). To assess the effect of (P)RR knockdown in cell growth or viability, a 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay (10009365, Cayman Chemical) was performed according to the manufacturer's protocol.
Statistical analysis. Continuous values were given as the median and interquartile range. Statistical comparisons were made using a Mann-Whitney U-test for two-group comparison and the KruskalWallis test, followed by a Mann-Whitney U-test for multiple comparisons of differences among the groups. Statistical significance was considered when P Ͻ 0.05.
RESULTS
(P)RR mRNA and protein expression. (P)RR mRNA was expressed in all tissues tested and PBMCs (Fig. 1A) . We also investigated the expression of (P)RR mRNA in T, B, NK cells, and monocytes after isolating PBMCs by flow cytometer sorting. (P)RR mRNA was highly expressed in T cells and NK cells (Fig. 1B) . A 39-kDa band corresponding to full-length (P)RR protein was clearly detected by Western blotting. Furthermore, we detected a very weak 28-kDa band corresponding to the soluble form of (P)RR protein (Fig. 1C) . Bands from (P)RR protein but not ␤-actin were abolished by preabsorption with human (P)RR 224 -237 peptide (Fig. 1D) .
(P)RR expression in human lymphocytes and monocytes. Positive (P)RR staining was observed in T cells (CD3 ϩ , Fig.  2A monocytes. E: negative controls. Middle: (P)RR ϩ lymphocytes or monocytes stained with (P)RR-specific antibodies (red). Right: merged pictures and nuclear stain with 4,5-diamidino-2-phenylindole (DAPI). Scale bars of low-power field ϭ 5 m and that of high-power field ϭ 50 m. nals suggested (P)RR might be expressed within the cell cytosol rather than on the cell surface except CD68 ϩ monocytes. In CD68 ϩ monocytes, the immune signals of (P)RR are overlapping with that of CD68. Isotype sera showed no positive immunofluorescence (Fig. 2E) .
(P)RR expression in human lymphocytes by flow cytometric analysis. Discrimination between targeted cells (lymphocytes and monocytes) and other cells (granular leukocytes and red blood cells) was achieved by forward and side scatter. PBMCs treated with anti-(P)RR antibodies showed (P)RR positivity compared with those treated with nonimmune rabbit serum (Fig. 3, A and B) . Samples treated with anti-(P)RR antibodies showed (P)RR positivity compared with those treated with nonimmune rabbit serum or isotype control (Fig. 3C) . Figure  3D shows a dot plot of (P)RR-positive cell rate from lymphocyte subsets and monocytes of 12 healthy subjects. The ex- pression level of (P)RR in monocytes, NK cells, and T cells was significantly higher than for B cells (P Ͻ 0.05). (P)RR expression tended to be high in monocytes compared with other cell types.
Renin-induced ERK phosphorylation and cytokine production. To investigate whether (P)RR in human lymphocytes and monocytes is functional, we focused on renin-induced ERK1/2 signaling. Human recombinant renin induction of ERK1/2 phosphorylation was renin concentration and time dependent (Fig. 4, A and B) . In this study, we used 20 nmol/l renin after stimulation experiments. Figure 4C shows a box plot of the ERK1/2 phosphorylation-positive cell rate before renin stimulation (prestimulated) and after stimulation (poststimulated) of PBMCs from nine healthy subjects. P-ERK-positive cells were significantly increased by renin stimulation (P Ͻ 0.01). Moreover, after isolation of each cell type (T cells, NK cells, and monocytes) from three volunteers, we analyzed renin-induced ERK1/2 phosphorylation. In respective cells, the histograms shifted to the right, suggesting ERK1/2 phosphorylation was induced by renin (Fig. 4D) . We could not investigate B cells because of low cell numbers in total lymphocytes.
We also examined whether cytokines were released after renin stimulation of PBMCs from six healthy subjects. Figure  5A indicates dot plots of each cytokine tested. The left and right panels show prestimulated (0 h) and poststimulated (after 24 h) levels, respectively. The release of IL-6, IL-10, and IFN-␥ was renin concentration and time dependent (Fig. 5B) . Furthermore, to determine which cells reacted to renin, we examined cytokine release after isolation of T, B, NK cells, and monocytes from PBMCs (n ϭ 6) by flow cytometer. IL-6 was mainly secreted by monocytes (Fig. 5C) .
To examine the effect of the ERK1/2 pathway on cytokine secretion, we performed the experiments using the ERK1/2 inhibitor U0126. We focused on IL-6 because this concentration was higher than the other cytokines after renin stimulation. Figure 6 indicates box plots of the change in each cytokine releasing with or without U0126 after stimulation of renin or Tris·HCl as a vehicle control. IL-6 in response to renin was significantly increased, and IL-6 was attenuated under U0126.
COX-2 expression. COX-2 is considered to be an important enzyme for the inflammatory reaction including the ERK1/2 pathway. To identify COX-2 expression via the ERK1/2 pathway after renin stimulation, we performed the experiments under ERK1/2 inhibitor U0126 using PBMCs from four healthy subjects. The expression of COX-2 was significantly increased by renin stimulation, and this expression was inhibited in the presence of U0126 (Fig. 7) .
(P)RR knockdown and ERK1/2 phosphorylation. To examine the response of ERK1/2 phosphorylation to renin via (P)RR, we knocked down (P)RR expression using siRNA in a human monocyte cell line (U937) because (P)RR expression was highest in monocytes and was expressed in macrophages infiltrating ANCAassociated GN. Human recombinant renin induction of ERK1/2 phosphorylation was renin concentration and time dependent in U937 cells (Fig. 8, A and B) . The greatest reduction of (P)RR expression (50%) was observed 48 h after (P)RR siRNA treatment (Fig. 8C) . The knockdown of (P)RR in U937 cells did not affect cell growth or viability (Fig. 8D ). ERK1/2 phosphorylation was significantly decreased by (P)RR siRNA treatment in U937 cells compared with control siRNA (Fig. 8E) .
(P)RR expression in human crescentic GN. To test whether (P)RR is expressed by inflammatory cells responsible for GN, renal tissues from three cases of ANCA-associated GN were stained (Fig. 9) . High numbers of macrophages (Fig. 9J) infiltrated around glomeruli. There were few infiltrating T cells (Fig.  9A) , B cells (Fig. 9D) , and NK cells (Fig. 9G) . Infiltrating T cells (Fig. 9B) , B cells (Fig. 9E ), NK cells (Fig. 9H) , and macrophages (Fig. 9K) around glomeruli with crescent formation and in the tubulointerstitium (Fig. 10A) were stained with (P)RR. By contrast, lymphocytes and macrophages did not infiltrate around glomeruli or the mesangium and tubulointerstitial area in the tissues of a control model, MCNS (Fig. 10B) .
DISCUSSION
The present study revealed the expression and functional role of (P)RR in human lymphocytes and monocytes, and (P)RR expression in tissue-infiltrating T cells and macrophages, that have a major role in the pathophysiology of ANCA-associated GN (40, 48) . (P)RR was present in the cellular cytosolic region. Both full-length and soluble forms of (P)RR were expressed in primary isolated PBMCs (Fig. 1C) . However, there is no visible band for THE soluble form of (P)RR (Fig. 1D) . This discrepancy might be due to the kinetics of soluble (P)RR. Generally, protein secretion has two distinct pathways: the regulated secretory pathway and the constitutive pathway (22) . Soluble (P)RR is considered to be secreted through the latter pathway and to be cleaved in the intracellular compartments of cells and secreted into the extracellular space over a short period of time without storage in post-Golgi vesicles (49) . The expression level of (P)RR was not affected by renin stimulation (data not shown). ERK1/2 phosphorylation, inflammatory cytokine secretion, and COX-2 expression were observed after renin stimulation. Thus (P)RR expressed by inflammatory cells is functionally active. In addition, (P)RR expression in infiltrating macrophages from the glomeruli and interstitium was observed in renal biopsy tissues from human crescentic GN. Feldt et al. showed ERK1/2 activation via (P)RR using various blockers, but not siRNA, in U937 cells. However, we used (P)RR siRNA and evaluated ERK1/2 phosphorylation in the same cell line.
To the best of our knowledge, this is the first study to demonstrate that functional (P)RR are expressed in a human monocyte cell line (13) , primary isolated monocytes and lymphocytes, and infiltrating T cells and macrophages of ANCAassociated GN. Moreover, renin stimulation induced secretion of inflammatory cytokines and expression of COX-2, an important enzyme for the inflammatory reaction, independently of angiotensin receptors.
Previous studies showed a relationship between the RAS and immunoreactions. The RAS exerts a deleterious effect through the induction of inflammatory responses. Inflammatory cells such as macrophages and T cells were significant sources of tissue ACE and contributed to increased local ANG II in atherosclerotic plaques of human coronary arteries (11) . Broad immunosuppression during ANG II-induced renal damage reduced albuminuria, inflammatory cell infiltration of the kidney, and renal structural damage through a blood pressure-independent mechanism (34) . Furthermore, AT 1 R is involved in the pathogenesis of glomerular injury in active immune complexmediated GN. ACE inhibitors and ANG II receptor blocker could have renoprotective benefits such as the reduction of proteinuria, glomerular extracellular matrix deposition, mesan- COX-2 expression in PBMCs in 4 healthy subjects after renin stimulation is shown. GAPDH was used as an internal control. The expression of COX-2 was significantly increased by renin stimulation, and this increase was inhibited in the presence of U0126, a specific ERK1/2 inhibitor. *P Ͻ 0.05.
gial cell activation, and renal plasminogen activator inhibitor-1 (PAI-1) independently of blood pressure control (17) . Moreover, ANG II induces various responses in human inflammatory cells, including NF-B activation (24) , chemotaxis in monocytes (23) , and modulation of intracellular redox status in neutrophils (12) as well as upregulating tissue RAS levels that activate T cells (9) . These results indicated the RAS is responsible for active GN and the immune responses derived from AT 1 R signaling. In this study, immune responses such as ERK1/2 phosphorylation, cytokine release, and COX-2 expression by renin stimulation in the presence of AT 1 R and AT 2 R blockers were observed in human inflammatory cells. We observed that induction of ERK1/2 phosphorylation was renin concentration dependent in the nanomolar range (Fig. 4A) , as previously reported (13) . However, plasma concentrations of prorenin and renin are in the picomolar range, and thus the interaction between renin/prorenin and (P)RR seems impossible except for renin/prorenin-synthesizing organs (25) . ( ANG II generation pathway in PBMCs after infiltration of the kidney.
(P)RR is a 350-amino acid protein with a single transmembrane domain (36) . When prorenin binds to (P)RR, it generates ANG I in the absence of cleavage of the prosegment (36) , and directly activates MAPK ERK1/2 signaling in several cell types, including mesangial cells (21, 36) , collecting duct cells (2), vascular smooth muscle cells (3, 14) , monocytes (13) , and neurons (8) . A previous study suggested that direct renin/ prorenin-induced ERK1/2 activation resulted in increased profibrotic gene expression, including TGF-␤1 and PAI-1, and thereby increased cell proliferation (51) . However, the activated ERK1/2 pathway in lymphocytes and monocytes induces secretion of cytokines including IL-6 and TNF-␤ in T cells (29) and and TNF-␣ (26) in monocytes. Moreover, ERK1/2 activation occurred in a rat Thy-1 model of mesangioproliferative nephritis, and blocking the ERK1/2 pathway resulted in a significant reduction of mesangial cell proliferation (5). In addition, ERK1/2 activation in human renal injury is associated with cell proliferation, histological deterioration, and renal dysfunction (31) . In our study, all experiments were performed in the presence of an AT 1 R blocker and AT 2 R blocker. These blockers did not have any effect on ERK1/2 phosphorylation and completely blocked ERK1/2 phosphorylation via the renin/ANG II pathway (data not shown). These findings with our study showing that renin stimulation of PBMCs induces ERK1/2 phosphorylation, cytokine release and COX-2 expression indicates (P)RR contributes to the pathophysiology of GN and renal injury via renin/prorenininduced ERK1/2 activation.
The (P)RR expression level in monocytes was high in our study. Monocytes/macrophages have inflammatory roles in renal disease and are implicated in the induction of injury and fibrosis. Many human biopsy studies have shown glomerular or interstitial macrophages correlate with poor outcomes, including progression of disease, severity of histopathological pre- sentation, likelihood of future fibrosis, or tubular atrophy (4, 15) . Through intracellular signaling pathways including MAPK, macrophages release several proinflammatory cytokines such as TNF-␣ and IL-6 and proinflammatory chemokines such as monocyte chemotactic protein (MCP), which is involved in the pathogenesis of crescentic GN (46) . Ozawa et al. (38) demonstrated chronic ANG II infusion in rats activated MCP-1 and TGF-␤1, which induced macrophage infiltration in renal tissues. Furthermore, TGF-␤1 is also associated with crescent formation in GN (41) , and MCP-1 and TGF-␤1 release is mediated by the RAS. Further studies are required to determine whether MCP-1 and TGF-␤1 are released by (P)RR stimulation.
In this study, we demonstrated that IL-6 was secreted from PBMCs stimulated by renin under AT 1 R and AT 2 R blockers. Actually, IL-6 was produced by a variety of cells including T cells and monocytes/macrophages (1, 45) , and IL-6 could contribute to the pathogenesis or progression of the renal diseases (16) . Moreover, the ERK1/2 pathway is considered to be important for the regulation of the production of IL-6 in the human kidney (28) . Therefore, (P)RR expressed in lymphocytes and monocytes may be involved in immune inflammatory responses mediated by proinflammatory cytokines such as IL-6 via the ERK1/2 pathway. Moreover, we demonstrated that COX-2, an important enzyme for the inflammatory reaction, was increased by renin and suppressed under an ERK inhibitor in human PBMCs. These experiments were performed in the presence of AT 1 R and AT 2 R blockers. Thus these immunoreactions including cytokine release and COX-2 expression were induced via (P)RR-mediated direct activation of the ERK1/2 pathway independently of ANG II in human primary PBMCs.
Finally, our flow cytometric data demonstrated that expression patterns of (P)RR in PBMCs differed among participants. Interestingly, some subjects had a higher percentage of (P)RRpositive cells than others (Fig. 3C) . We did not identify specific characteristics, such as sex, age, habit, past history, shape of the body, or biomarkers that may have accounted for this difference. Therefore, the cause of different (P)RR expression levels is unclear and should be studied further. We also examined the relationship between T cell subpopulations and (P)RR expression because T cells have an important role in GN. However, we did not identify a significant correlation between T cell subpopulations and (P)RR expression.
Several limitations should be acknowledged. It was very difficult to transfect siRNA into human lymphocytes and monocytes and maintain cell viability. Our results also revealed that (P)RR expression in monocytes was high and that (P)RR was expressed by ANCA-associated GN-infiltrating macrophages. Therefore, we used a human leukemic monocyte lymphoma cell line, U937 cells, to overcome these issues. Moreover, we showed that (P)RR was expressed in lymphocytes and macrophages infiltrating in GN. However, the number of samples was insufficient, and the pathophysiological functions of (P)RR in GN are still unclear. We examined the expression of (P)RR in PBMCs from healthy subjects, and future studies should investigate (P)RR expression in GN patients. Although the role of soluble (P)RR in inflammation is unclear, there is no currently available antibody that fully discriminates the soluble and full-length forms of (P)RR. In addition, further investigations using larger human sample sizes and various disease conditions, and animal models of GN such as ANCA-treated or transgenic mice models, are required to clarify the association of lymphocyte (P)RR expression and the immune system. In conclusion, the present study demonstrated for the first time that functional (P)RR is expressed by human immune cells, especially monocytes and NK cells, and is expressed in infiltrating lymphocytes and macrophages during active GN such as ANCA-associated GN. These findings indicate that (P)RR contributes to inflammation as a RAS component during active GN, independently of the AT 1 R pathway.
